Revolade
Novartis’ Promacta cleared by FDA for first-line use in severe aplastic anaemia
November 19, 2018Sales and Marketing FDA, Novartis, Promacta, Revolade, US, aplastic anaemia, pharma
Novartis has secured expanded approval from the FDA for Promacta (eltrombopag), allowing it to now be used in combination with …
Novartis presents strong results in rare blood disorder trials
June 10, 2016Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder
Novartis has released data from two late-stage trials for rare blood disorders, which showed that Javi (ruxolitinib) is superior to …
Novartis receives EU approval for blood disorder treatment in children
April 7, 2016Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp
Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …
GSK submits new Promacta licence
March 3, 2014Sales and Marketing GSK, NICE, Promacta, Revolade, blood, eltrombopag
GlaxoSmithKline is seeking a new licence for its blood disorder drug Promacta in patients with severe aplastic anaemia. Specifically, the …
GSK’s Promacta extends US licence
November 22, 2012Sales and Marketing FDA, GSK, Promacta, Revolade
GlaxoSmithKline’s Promacta has received a new indication from the FDA which means it can be used for patients with thrombocytopenia …
GSK guilty of off-label promotion
November 9, 2012Medical Communications, Sales and Marketing GSK, PMCPA, Revolade
GlaxoSmithKline has been found to have breached three clauses in the ABPI Code of Practice following a complaint from a …
NICE rejects GSK’s Revolade
June 10, 2010Sales and Marketing ITP, NICE, Revolade
NICE has rejected GlaxoSmithKline’s Revolade saying in draft guidance that the blood disorder drug’s benefits were unclear. The watchdog assessed …
Revolade gets European go ahead
March 15, 2010Sales and Marketing GlaxoSmithKline, Revolade, thrombocytopenia
European regulators have approved GlaxoSmithKline’s Revolade to treat reduced platelet count in patients with a rare blood disorder. Revolade (eltrombopag) …
